
Acutaas Chemicals shares surged 13% to hit a record high of ₹3,900 during Tuesday's intraday trading, significantly outperforming the broader market. According to LiveMint, the stock surpassed its previous high of ₹3,796 touched on October 27, 2026, demonstrating exceptional investor confidence following the company's strong September quarter results. The pharmaceutical company's market price has zoomed 119% in the last 12 months, with the stock gaining 580% over five years - a remarkable long-term performance that positions it as a standout multibagger stock. This exceptional performance comes as the stock has jumped 16% in one month, 52% in six months, and 119% in the last year, with the stock trading close to its 52-week high of ₹3,900.
According to LiveMint, Acutaas Chemicals delivered exceptional September quarter results that drove significant investor confidence. The company reported revenue of ₹437 crore for the September quarter, marking a 42.8% increase from ₹306 crore in the corresponding period last year. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) climbed 86.3% year-on-year to ₹177 crore from ₹95 crore, while EBITDA margin expanded sharply to 40.5%, compared with 31% a year earlier. The gross margin for the quarter improved significantly to 62.1%, up 637 basis points year-on-year. Profit after tax (PAT) for the quarter jumped 71.4% YoY to ₹123.1 crore, reflecting the company's strong operational performance across all key metrics. For the half-year period (H1 FY27), revenue from operations increased by 49.3% to ₹766.6 crore, up from ₹513.4 crore in H1 FY26, as reported by Acutaas Chemicals.
As reported by LiveMint, Acutaas Chemicals has revised its financial year 2027 guidance upward following the strong quarterly performance. The company increased its revenue growth guidance from 25% to around 30% for FY27, with management citing improved revenue visibility and a robust order pipeline as key confidence factors. Additionally, the company revised its EBITDA margin guidance higher to the 38-40% range for the full year. The management attributed the growth during the quarter to continued momentum in the Pharmaceutical Intermediates business, which was offset by softer performance in the Specialty Chemicals segment. According to LiveMint, a significant milestone during the quarter was the early inauguration of the company's South Korea manufacturing facility, which is equipped to manufacture high-purity chemicals used in photoresists, semiconductor packaging materials, etching materials and other semiconductor applications. Gross profit for the quarter rose by 59.0% to ₹271.5 crore, with the gross margin improving to 62.1%, as reported by Acutaas Chemicals.
According to LiveMint, the CDMO business and core advanced intermediate business delivered robust growth during the quarter, while the specialty chemicals business remained subdued. The BFC business was impacted during the quarter due to change in ownership of the US customer. The company operates as a specialty chemicals manufacturer serving pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals, with core strength in research-driven development of advanced pharmaceutical intermediates. Acutaas Chemicals is well-positioned to capitalize on the Indian CDMO market expansion, valued at $8.52 billion in 2025 and projected to reach $16.53 billion by 2034, driven by increasing pharmaceutical outsourcing and the China+1 strategy adoption.
As reported by LiveMint, the company is positioned to benefit from India's semiconductor market growth, which was valued at $59.78 billion in 2025 and projected to reach $180.20 billion by 2034, growing at an 11.95% CAGR from 2026 to 2034. This expansion is fueled by government initiatives like the ₹76,000 crore PLI scheme and surging demand from AI, 5G, and electric vehicles. The Indian semiconductor ecosystem is experiencing massive industrial projects, including Tata Electronics' $11 billion fab and Micron's assembly facility in Gujarat, creating significant opportunities for specialty chemical manufacturers. The company noted that growth is accelerated by massive industrial projects and the digital economy scaling towards $1 trillion, with demand for ultrapure materials and specialized chemicals remaining a critical tailwind for the domestic chemical industry.